HRP20090571T1 - Pharmaceutical composition comprising cyclic somatostatin analogues - Google Patents
Pharmaceutical composition comprising cyclic somatostatin analoguesInfo
- Publication number
- HRP20090571T1 HRP20090571T1 HR20090571T HRP20090571T HRP20090571T1 HR P20090571 T1 HRP20090571 T1 HR P20090571T1 HR 20090571 T HR20090571 T HR 20090571T HR P20090571 T HRP20090571 T HR P20090571T HR P20090571 T1 HRP20090571 T1 HR P20090571T1
- Authority
- HR
- Croatia
- Prior art keywords
- ala
- pharmaceutical composition
- amino acid
- formula
- somatostatin analogues
- Prior art date
Links
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 235000019253 formic acid Nutrition 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314695A GB0314695D0 (en) | 2003-06-24 | 2003-06-24 | Organic compounds |
| GB0325388A GB0325388D0 (en) | 2003-10-30 | 2003-10-30 | Organic compounds |
| PCT/EP2004/006794 WO2005000893A2 (fr) | 2003-06-24 | 2004-06-23 | Composition pharmaceutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090571T1 true HRP20090571T1 (en) | 2009-11-30 |
Family
ID=33554159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090571T HRP20090571T1 (en) | 2003-06-24 | 2009-10-27 | Pharmaceutical composition comprising cyclic somatostatin analogues |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20070093412A1 (fr) |
| EP (1) | EP1648934B1 (fr) |
| JP (1) | JP4746541B2 (fr) |
| KR (1) | KR101124136B1 (fr) |
| AR (1) | AR044852A1 (fr) |
| AT (1) | ATE438659T1 (fr) |
| AU (1) | AU2004251866B2 (fr) |
| BR (1) | BRPI0411820B8 (fr) |
| CA (1) | CA2529449C (fr) |
| CL (1) | CL2004001579A1 (fr) |
| CO (1) | CO5650225A2 (fr) |
| CY (1) | CY1109444T1 (fr) |
| DE (1) | DE602004022420D1 (fr) |
| DK (1) | DK1648934T3 (fr) |
| EC (1) | ECSP056237A (fr) |
| ES (1) | ES2328144T3 (fr) |
| HK (1) | HK1089776A1 (fr) |
| HR (1) | HRP20090571T1 (fr) |
| IL (1) | IL172329A (fr) |
| IS (1) | IS2705B (fr) |
| MA (1) | MA27862A1 (fr) |
| MX (1) | MXPA05013821A (fr) |
| MY (1) | MY145375A (fr) |
| NO (1) | NO330706B1 (fr) |
| NZ (1) | NZ544157A (fr) |
| PE (1) | PE20050285A1 (fr) |
| PL (1) | PL1648934T3 (fr) |
| PT (1) | PT1648934E (fr) |
| RU (1) | RU2355418C2 (fr) |
| SI (1) | SI1648934T1 (fr) |
| TW (1) | TWI361194B (fr) |
| WO (1) | WO2005000893A2 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100273719A1 (en) | 2007-11-28 | 2010-10-28 | Novartis Ag | Use of somatostatin analogs in meningioma |
| ES2431573T3 (es) * | 2007-12-03 | 2013-11-27 | Italfarmaco S.P.A. | Nuevos análogos no selectivos de somatostatina |
| FR2942227B1 (fr) * | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
| TWI633887B (zh) * | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及／或治療多囊性腎臟病之藥物 |
| PT3053916T (pt) * | 2013-09-30 | 2019-03-26 | Ono Pharmaceutical Co | Composto com atividade agonista do recetor da somatostatina e utiliza ao farmaceutica do mesmo |
| CN104447962B (zh) * | 2014-12-29 | 2018-07-17 | 成都圣诺生物科技股份有限公司 | 一种合成帕瑞肽的方法 |
| GB201816637D0 (en) | 2018-10-12 | 2018-11-28 | Heptares Therapeutics Ltd | Selective somatostatin receptor agonists |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4328214A (en) * | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
| EP0083305B1 (fr) * | 1981-12-24 | 1985-07-10 | Ciba-Geigy Ag | Octapeptides cycliques, préparations pharmaceutiques les contenant et procédés de leur préparation et leur utilisation |
| US4612366A (en) * | 1985-06-17 | 1986-09-16 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| JPH02111A (ja) * | 1987-08-03 | 1990-01-05 | Toyo Jozo Co Ltd | 経鼻投与用生理活性ペプチド製剤 |
| US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
| JP2641755B2 (ja) | 1988-01-29 | 1997-08-20 | 住友製薬株式会社 | コントロールリリース製剤 |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5716596A (en) | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
| EP1099707A3 (fr) | 1993-06-23 | 2002-01-09 | Diatide, Inc. | Peptides derives de la somatostatine et marques de maniere radioactive pour imagerie et utilisations therapeutiques |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| MY147327A (en) * | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| ES2167189B1 (es) | 1999-12-17 | 2003-04-01 | Lipotec Sa | Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos |
| GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| SI2310042T1 (sl) * | 2008-07-08 | 2013-03-29 | Novartis Ag | Uporaba pasireotida za zdravljenje endogene hiperinzulinemične hipoglikemije |
-
2004
- 2004-06-22 PE PE2004000610A patent/PE20050285A1/es not_active Application Discontinuation
- 2004-06-22 AR ARP040102163A patent/AR044852A1/es not_active Application Discontinuation
- 2004-06-23 CA CA2529449A patent/CA2529449C/fr not_active Expired - Lifetime
- 2004-06-23 AU AU2004251866A patent/AU2004251866B2/en active Active
- 2004-06-23 WO PCT/EP2004/006794 patent/WO2005000893A2/fr active Search and Examination
- 2004-06-23 NZ NZ544157A patent/NZ544157A/en not_active IP Right Cessation
- 2004-06-23 SI SI200431269T patent/SI1648934T1/sl unknown
- 2004-06-23 RU RU2006101720/15A patent/RU2355418C2/ru active Protection Beyond IP Right Term
- 2004-06-23 MY MYPI20042450A patent/MY145375A/en unknown
- 2004-06-23 EP EP04740213A patent/EP1648934B1/fr not_active Expired - Lifetime
- 2004-06-23 PL PL04740213T patent/PL1648934T3/pl unknown
- 2004-06-23 ES ES04740213T patent/ES2328144T3/es not_active Expired - Lifetime
- 2004-06-23 KR KR1020057024845A patent/KR101124136B1/ko active IP Right Grant
- 2004-06-23 AT AT04740213T patent/ATE438659T1/de active
- 2004-06-23 TW TW093118140A patent/TWI361194B/zh active
- 2004-06-23 CL CL200401579A patent/CL2004001579A1/es unknown
- 2004-06-23 BR BRPI0411820A patent/BRPI0411820B8/pt active IP Right Grant
- 2004-06-23 DK DK04740213T patent/DK1648934T3/da active
- 2004-06-23 JP JP2006516037A patent/JP4746541B2/ja not_active Expired - Lifetime
- 2004-06-23 US US10/560,751 patent/US20070093412A1/en not_active Abandoned
- 2004-06-23 MX MXPA05013821A patent/MXPA05013821A/es active IP Right Grant
- 2004-06-23 DE DE602004022420T patent/DE602004022420D1/de not_active Expired - Lifetime
- 2004-06-23 PT PT04740213T patent/PT1648934E/pt unknown
-
2005
- 2005-12-01 IL IL172329A patent/IL172329A/en active IP Right Grant
- 2005-12-19 EC EC2005006237A patent/ECSP056237A/es unknown
- 2005-12-21 MA MA28680A patent/MA27862A1/fr unknown
- 2005-12-27 CO CO05130258A patent/CO5650225A2/es not_active Application Discontinuation
-
2006
- 2006-01-20 IS IS8247A patent/IS2705B/is unknown
- 2006-01-24 NO NO20060375A patent/NO330706B1/no unknown
- 2006-09-08 HK HK06110030.5A patent/HK1089776A1/xx unknown
-
2009
- 2009-01-26 US US12/359,527 patent/US8299209B2/en active Active
- 2009-09-30 CY CY20091101022T patent/CY1109444T1/el unknown
- 2009-10-27 HR HR20090571T patent/HRP20090571T1/xx unknown
-
2012
- 2012-09-27 US US13/628,900 patent/US20130035286A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090571T1 (en) | Pharmaceutical composition comprising cyclic somatostatin analogues | |
| BR9609335B8 (pt) | Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos. | |
| HUP0003592A2 (hu) | LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények | |
| TW200631592A (en) | Soluble, stable insulin-containing formulations | |
| EP0340741A3 (fr) | Dérivés de polyéthylèneglycol, peptides modifiés et leur production | |
| DE69839812D1 (de) | Analoge des menschlichen interferon-alpha mit niedriger toxizität | |
| ATE367398T1 (de) | Verfahren zur rückfaltung von proteinen mit freien cysteinresten | |
| HUP0300684A2 (hu) | Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ATE489462T1 (de) | Antimikrobielles polypeptid und nutzung davon | |
| ATE446313T1 (de) | Muteine von tränen-lipocalin | |
| IL175319A0 (en) | Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof | |
| RU2006120484A (ru) | Микрочастицы, содержащие аналоги соматостатина | |
| ATE430165T1 (de) | Peptide mit integrinbindungsmotiv und behandlungsmethoden für muskelkrankheiten | |
| EA200000378A1 (ru) | Усеченные по амино-концу мср-2 как антагонисты хемокинов | |
| ATE364079T1 (de) | Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung | |
| DE3780000T2 (de) | Peptidverbindungen. | |
| MX2009002962A (es) | Peptidos antibacterianos y antivirales de actinomadura namibiensis. | |
| WO2005004899A3 (fr) | Substances a activite biologique du peptide intestinal vasoactif pour le traitement d'affections pulmonaires interstitielles | |
| HUP0301396A2 (hu) | Integrin inhibitor hatású peptid- és peptidutánzó konjugátumok, azokat tartalmazó implantátumok és alkalmazásuk | |
| ATE551353T1 (de) | Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten | |
| DE60237784D1 (de) | Verfahren zur verabreichung eines thymosin-alpha 1 peptids | |
| DK1506295T3 (da) | Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf | |
| RU2006106721A (ru) | Получение пептидов соматостатина | |
| AR004497A1 (es) | Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica. | |
| DE69834929D1 (de) | Verwendung eines organspezifischen ernährungmittels |